MedPath

A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

Phase 1
Active, not recruiting
Conditions
Pancreatic Cancer
Colorectal Cancer
Gastric Cancer
Ovarian Cancer
Interventions
Drug: CUE-102
Registration Number
NCT05360680
Lead Sponsor
Cue Biopharma
Brief Summary

This is a Phase 1, open-label, 2-part, multi-center study evaluating the safety, tolerability, PK, pharmacodynamics (PD), immunogenicity, and antitumor activity of CUE-102 intravenous (IV) monotherapy in HLA-A\*0201 positive patients with WT1 positive recurrent/metastatic solid tumors who have failed conventional therapies.

Detailed Description

CUE-102 is a novel fusion protein developed for the treatment of patients with WT1-positive malignancies by selective engagement and expansion of tumor antigen-specific T cells that should allow for increased potential for anti-cancer efficacy and reduced toxicity relative to non-targeted forms of immunotherapy that result in systemic activation of the immune system.

The goal of Part A is to characterize the safety, tolerability, and biological effects of CUE-102.

The goal of Part B is to expand the safety and immune activity data at the RP2D identified in Part A, and to evaluate antitumor activity at this dose.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
52
Inclusion Criteria

  1. Ability to provide informed consent and documentation of informed consent prior to initiation of any study-related tests or procedures that are not part of standard of care for the patient's disease.

  2. Age ≥18 years old

  3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

  4. Life expectancy ≥12 weeks

  5. Measurable disease as per RECIST 1.1 and documented by CT and/or MRI.

  6. All tumors must have histologically or cytologically confirmed cancer diagnosis

  7. Patients must have any of the following cancers to be eligible:

    A. Colorectal cancer

    1. Histologically or cytologically documented adenocarcinoma of colon or rectum at the time of initial presentation
    2. Metastatic or locally advanced/unresectable disease
    3. Documented disease progression after the last administration of standard therapies or intolerance to at least 2 prior systemic treatment regimens (CUE-102 will be 3rd line therapy or greater).

    B. Gastric cancer (including gastroesophageal junction)

    1. Histologically or cytologically documented gastric cancer at the time of initial presentation
    2. Metastatic or locally advanced/unresectable disease
    3. Documented disease progression after last administration of standard therapies or intolerance to standard therapies. (CUE-102 will be 2nd line therapy or greater).

    C. Pancreatic cancer

    1. Histologically or cytologically documented pancreatic adenocarcinoma at the time of initial presentation
    2. Patients with metastatic or locally advanced/unresectable disease.
    3. Prior systemic treatment must include either a fluoropyrimidine-based or gemcitabine-based regimen in either the (neo)adjuvant or relapsed setting. (CUE-102 will be 2nd line therapy or greater).

    D. Ovarian cancer

    1. Histologically or cytologically documented ovarian cancer at the time of initial presentation
    2. Metastatic or locally advanced/unresectable disease, with documented disease progression after last administration of standard therapies or intolerance to standard therapies.
    3. Prior systemic treatment must include a platinum-based regimen. (CUE-102 will be 2nd line therapy or greater).
    4. For patients determined to have platinum-sensitive disease, treatment with a second platinum-based combination regimen +/- bevacizumab should be considered prior to treatment with CUE-102 (CUE-102 will be 3rd line therapy or greater).

  8. Patient must have HLA-A*0201 genotype as determined by genomic testing.

  9. Patient must have histologically and/or cytologically proven tumor(s) that is WT1 positive.

  10. Acceptable laboratory parameters.

  11. Female patients of childbearing potential must agree to use acceptable contraceptive measures from the time of main study consent through 90 days after discontinuation of study drug administration.

  12. Non-vasectomized male patients with partners of childbearing potential must use barrier contraception from the time of main study consent through 90 days after discontinuation of study drug.

  13. Patients who have previously received an immune CPI (e.g., anti-programmed cell death ligand 1 (anti PD-L1), anti-programmed cell death 1 (anti-PD-1), anti-cytotoxic T lymphocyte-associated antigen 4 [CTLA-4]) prior to enrollment must have toxicities related to the CPI resolved to CTCAE ≤ Grade 1 or baseline (level prior to the CPI) to be eligible for enrollment. Patients who have experienced CPI-related endocrinopathies (e.g., diabetes, adrenal insufficiency) may participate if endocrinopathies are controlled (CTCAE ≤ Grade 1) with endocrinology support and appropriate repletion. Note: Patients who experienced previous hypothyroidism toxicity on a CPI are eligible to enter study regardless of CTCAE grade resolution as long as the patient is well controlled on thyroid replacement hormone.

Read More
Exclusion Criteria

  1. Female patients who are pregnant or plan to become pregnant during the course of the trial

  2. Female patients who are breastfeeding

  3. Patients with symptomatic central nervous system (CNS) metastases must have been treated, be asymptomatic, and not have any of the following at the time of enrollment:

    1. Need for concurrent treatment for the CNS disease (e.g., surgery, radiation, corticosteroids >10 mg prednisone/day or equivalent)
    2. Progression of CNS metastases on CT or MRI for at least 28 days after last day of prior therapy for the CNS metastases
    3. Concurrent leptomeningeal disease or cord compression.

  4. Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is permitted.

  5. History of prior allogeneic bone marrow, stem-cell, or solid organ transplantation

  6. Treatment with any systemic anti-neoplastic therapy, or investigational therapy within the 14 days (or 28 days, for antibody drugs), before the first dose of CUE-102.

  7. Treatment with radiation therapy within 14 days before the first dose of CUE-102

  8. Treatment with corticosteroids (> 10 mg per day prednisone or equivalent) or other immune suppressive drugs within 14 days before the first dose of CUE-102. Steroids for topical, ophthalmic, inhaled, or nasal administration are permitted. Physiological replacement with up to a maximum dose of 5 mg equivalence of prednisone per day is permitted.

  9. History of clinically significant cardiovascular disease

  10. Clinically significant pulmonary compromise (e.g., requirement for supplemental oxygen)

  11. Clinically significant gastrointestinal (GI) disorders

  12. Patients who experienced the following immune CPI-related AEs are ineligible even if the AE resolved to ≤ Grade 1 or baseline:

    1. ≥ Grade 3 ocular AE
    2. Changes in liver function tests that met the criteria for Hy's Law (> 3× ULN of either ALT/AST with concurrent > 2× ULN of total bilirubin (total and direct) and without alternate etiology)
    3. ≥ Grade 3 neurologic toxicity
    4. ≥ Grade 3 colitis
    5. ≥ Grade 3 renal toxicity

  13. Evidence of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days before the first dose of CUE-102.

  14. No known history of infection or positive test for HIV, Hepatitis B or Hepatitis C, testing prior to enrollment is not required unless mandated by local authority

  15. Second primary invasive malignancy that has not been in remission for > 2 years.

  16. History of trauma or major surgery within 28 days before the first dose of CUE-102

  17. Any serious underlying medical or psychiatric condition that would impair the ability of the patient to receive or tolerate the planned treatment at the investigational site

  18. Known hypersensitivity to recombinant proteins, polysorbate 80 or any excipient contained in the drug formulation for CUE-102

  19. Vaccination with any live virus vaccine within 28 days before the first dose of CUE-102. Inactivated annual influenza vaccination is allowed.

  20. Dementia or altered mental status that would preclude understanding and rendering of informed consent

  21. Active or history of significant alcohol or other substance abuse within 1 year before the first dose of CUE-102

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Arm && Interventions
GroupInterventionDescription
CUE-102 (2 mg/kg) Dose EscalationCUE-102CUE-102 (2 mg/kg) Monotherapy IV infusion every 3 weeks for up to 2 years
CUE-102 Dose Expansion at Determined RP2DCUE-102Dose expansion of CUE-102 at determined RP2D Monotherapy IV infusion every 3 weeks for up to 2 years
CUE-102 (1mg/kg) Dose EscalationCUE-102CUE-102 (1 mg/kg) Monotherapy IV infusion every 3 weeks for up to 2 years
CUE-102 (4 mg/kg) Dose EscalationCUE-102CUE-102 (4 mg/kg) Monotherapy IV infusion every 3 weeks for up to 2 years
CUE-102 (8 mg/kg) Dose EscalationCUE-102CUE-102 (8 mg/kg) Monotherapy IV infusion every 3 weeks for up to 2 years
Primary Outcome Measures
NameTimeMethod
Serum PK Cmax for CUE-102Up to 2 years

Maximum serum concentration (Cmax) of CUE-102.

Serum PK AUC for CUE-102Up to 2 years

Area under the concentration-time curve (AUC) of CUE-102.

Serum PK T1/2 for CUE-102Up to 2 years

Terminal half-life (T1/2) of CUE-102.

Dose Limiting Toxicity21 Days

Evaluate dose-limiting toxicities (DLTs) during the first cycle of treatment with CUE-102, and to establish a recommended Phase 2 dose (RP2D)

Maximum Tolerated Dose21 Days

Evaluate maximum tolerated dose (MTD) to establish a recommended Phase 2 dose (RP2D)

Secondary Outcome Measures
NameTimeMethod
Safety and Tolerability of CUE-102 Assessed by NCI CTCAE v5.0Up to 2 years

To evaluate safety and tolerability of CUE-102 using NCI CTCAE v5.0.

Antitumor Duration of Response with Treatment of CUE-102Up to 2 years

To evaluate antitumor duration of response of CUE-102 by RECIST 1.1

Immune Response Assessed by WW1 Tetramer-Positive T cell LymphocytesUp to 2 years

To evaluate the potential for immune response after treatment with CUE-102 using assessment of number of WT1 tetramer-positive T cell lymphocytes.

Antitumor Response Rate with Treatment of CUE-102Up to 2 years

To evaluate antitumor response rate of CUE-102 by RECIST 1.1

Immune Response Assessed by CTL Markers of ActivationUp to 2 years

To evaluate the potential for immune response after treatment with CUE-102 using assessment of cytotoxic T lymphocyte (CTL) markers of activation

Antitumor Clinical Benefit Rate with Treatment of CUE-102Up to 2 years

To evaluate antitumor clinical benefit rate of CUE-102 by RECIST 1.1

Overall Survival with Treatment of CUE-102From First CUE-102 to Date of Death

To evaluate overall survival after treatment with CUE-102

Progression-Free Survival with Treatment of CUE-102Up to 2 years

To evaluate antitumor progression-free survival of CUE-102 by RECIST 1.1

Trial Locations

Locations (15)

Stanford Advanced Medicine Cancer Center

🇺🇸

Palo Alto, California, United States

Cedars-Sinai Medical Center

🇺🇸

Los Angeles, California, United States

Northwest Medical Specialties, PLLC

🇺🇸

Tacoma, Washington, United States

Winship Cancer Institute

🇺🇸

Atlanta, Georgia, United States

Johns Hopkins University

🇺🇸

Baltimore, Maryland, United States

Gabrail Cancer Center

🇺🇸

Canton, Ohio, United States

Carolina BioOncology Institute

🇺🇸

Huntersville, North Carolina, United States

Cleveland Medical Center (University Hospitals)

🇺🇸

Cleveland, Ohio, United States

Mayo Clinic

🇺🇸

Phoenix, Arizona, United States

MD Anderson Cancer Center

🇺🇸

Houston, Texas, United States

Mayo Clinic - Rochester

🇺🇸

Rochester, Minnesota, United States

Carol G. Simon Cancer Center - Morristown Medical Center

🇺🇸

Morristown, New Jersey, United States

Moffitt Cancer Center

🇺🇸

Tampa, Florida, United States

Carbone Cancer Center

🇺🇸

Madison, Wisconsin, United States

Montefiore Medical Center

🇺🇸

Bronx, New York, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy